Mon-Fri 9:00-18:00 CET+39 095 7211344info@vitasanlabs.com

Family · Pharmaceutical analytical standards

Naltrexone

A long-acting opioid antagonist, synthesised in 1963 and approved in the United States in 1984: it is used to treat opioid dependence and, since the mid-1990s, alcohol dependence. This family brings together the active ingredient, pharmacopoeial impurities, metabolites, labelled standards and other impurities.

Did you know?It is an almost 'pure' antagonist: it binds opioid receptors without activating them and displaces molecules already bound there, with a long-lasting effect.

NaltrexoneGo to the active ingredient →
NaltrexoneActive ingredientNaltrexoneCat. No. P-N018-001CAS 16590-41-3
Naltrexone-d3Isotopically labelledNaltrexone-d3Cat. No. P-N018-020CAS 1261080-26-5
Naltrexone-d4Isotopically labelledNaltrexone-d4Cat. No. P-N018-021CAS 2070009-29-7

EDQM standards 2

The official European Pharmacopoeia standards for this family.

Need a molecule you cannot find?

Custom synthesis of impurities, metabolites and labelled compounds, with the same characterisation level.